MM-099: Mezigdomide (MEZI) Plus Dexamethasone (DEX) and Bortezomib (BORT) or Carfilzomib (CFZ) in Patients With Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results From the CC-92480-MM-002 Trial — Irwindeep Sandhu (2025) | RDL Network
MM-099: Mezigdomide (MEZI) Plus Dexamethasone (DEX) and Bortezomib (BORT) or Carfilzomib (CFZ) in Patients With Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results From the CC-92480-MM-002 Trial
Irwindeep Sandhu, Paul G. Richardson, Albert Oriol, Darrell White, Richard LeBlanc, Noopur Raje, Enrique M. Ocio, Aurore Perrot, Thierry Façon, Cesar Rodriguez, Ralph Wäsch, Meletios A Dimopoulos, Tracy T. Chow, Allison Gaudy, Jing Gong, Zehua Zhou, Tiziana Civardi, Joseph T. Hadala, Yue Zhu, Jessica Katz, Marc S. Raab
Paul G. Richardson, Irwindeep Sandhu, Albert Oriol, Marc S. Raab, Darrell White, Richard Leblanc, Aurore Perrot, Enrique M. Ocio, Noopur Raje, Charlotte Toftmann Hansen, Ze‐Hua Zhou, Tiziana Civardi, Alessandro Ghiddi, Jessica Katz, Teresa Peluso, Meletios A Dimopoulos
Scott Goldsmith, Albert Oriol, Pekka Anttila, Nizar J. Bahlis, Jesús G. Berdeja, Andrew J. Cowan, Meletios A Dimopoulos, Laahn Foster, Jens Hillengaß, Martha Louzada, Ka Lung Wu, Tracy Chow, Wen‐Cong Chen, Yue Wang, Alessia Spirlì, Phillip J. Koo, Paulo Maciag, Daniel Zhu, Jessica Katz, Paul G. Richardson
Morten Salomo, Enrique M. Ocio, Carmen Martínez‐Chamorro, Sosana Delimpasi, Albert Oriol, Meletios A Dimopoulos, Xavier Leleu, Samuel M. Rubinstein, Nisha S. Joseph, Mercedes Gironella, Rajshekhar Chakraborty, Carlos Fernández-de Larrea, Aurora Breazna, James Drew, Anita Boyapati, Anasuya Hazra, Glenn S. Kroog, Shawn Sarkaria, Paula Rodríguez‐Otero
Morten Salomo, Enrique M. Ocio, Carmen Martínez‐Chamorro, Sosana Delimpasi, Albert Oriol, Meletios A Dimopoulos, Xavier P. Leleu, Sam Rubinstein, Nisha S. Joseph, Mercedes Gironella, Rajshekhar Chakraborty, Carlos Fernández de Larrea, Aurora Breazna, James Drew, Anita Boyapati, Anasuya Hazra, Glenn S. Kroog, Shawn Sarkaria, Paula Rodríguez‐Otero
Discussion(0)
No comments yet. Be the first to comment.